Foresite Capital Management IV’s Cytokinetics CYTK Stock Holding History

Foresite Capital Management IV’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$60.9M	Buy	714,695 +211,400	+42%	+$15.2M	20.98%	2
2026 Q1	$33.2M	Buy	503,295 +45,000	+10%	+$2.86M	13.99%	2
2025 Q4	$29.1M	Hold	458,295	–	–	12.68%	2
2025 Q3	$25.2M	Buy	+458,295	New	+$18.9M	13.79%	2
2021 Q3	–	Sell	-545,101	Closed	-$10.8M	–	13
2021 Q2	$10.8M	Sell	545,101 -336,800	-38%	-$7.91M	1.46%	9
2021 Q1	$20.5M	Sell	881,901 -554,091	-39%	-$11.8M	2.46%	9
2020 Q4	$29.8M	Sell	1,435,992 -236,300	-14%	-$4.32M	3.24%	8
2020 Q3	$36.2M	Buy	1,672,292 +65,000	+4%	+$1.52M	8.16%	6
2020 Q2	$37.9M	Sell	1,607,292 -570,000	-26%	-$10.7M	18.45%	2
2020 Q1	$25.7M	Sell	2,177,292 -221,678	-9%	-$2.83M	31.64%	1
2019 Q4	$25.5M	Buy	2,398,970 +500,000	+26%	+$5.14M	10.98%	4
2019 Q3	$21.6M	Hold	1,898,970	–	–	6.98%	6
2019 Q2	$21.4M	Buy	1,898,970 +175,800	+10%	+$1.7M	6.04%	5
2019 Q1	$13.9M	Buy	1,723,170 +1,548,022	+884%	+$11.4M	5.01%	9
2018 Q4	$1.11M	Buy	+175,148	New	+$1.28M	0.51%	18

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Foresite Capital Management IV's CYTK Position: Q2 2026 in Review

Foresite Capital Management IV increased its Cytokinetics (CYTK) stake by 42% in Q2 2026, buying an estimated $15.2M and bringing the position to 714,695 shares worth $60.9M. The position accounts for 20.98% of the portfolio, ranked #2.

Foresite Capital Management IV first reported a position in CYTK in Q4 2018 and has held it in 15 quarters since. 483 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Foresite Capital Management IV held 714,695 shares of Cytokinetics worth $60.9M as of Q2 2026.
Foresite Capital Management IV bought 211,400 Cytokinetics shares in Q2 2026, an estimated $15.2M.
Cytokinetics made up 20.98% of Foresite Capital Management IV's portfolio in Q2 2026, its #2 holding.
Foresite Capital Management IV first reported a position in Cytokinetics in Q4 2018 and has held it in 15 quarters since.
483 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Foresite Capital Management IV's 13F filing for Q2 2026, filed 14 Aug 2026.